Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00843089 · ClinicalTrials.gov registry record · NA

Secondary Prevention After Coronary Bypass Surgery

A NA study of Coronary Artery Disease, sponsored by Jeffrey Kramer, MD.

Completed
Registry status
NA
Development phase
115
Enrollment target
1
Study location

NCT00843089 is a NA study of Coronary Artery Disease that has completed, run by Jeffrey Kramer, MD. The registered enrollment target is 115 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00843089, a NA study of Coronary Artery Disease, has completed, sponsored by Jeffrey Kramer, MD.

COMPLETED
Registry status
NA
Development phase
115 participants
Enrollment target
1
Study location

Study Summary

Despite immediate symptomatic success after coronary bypass surgery in patients with coronary artery disease, this effect is not sustained over time since risk factors for coronary artery disease are still in place. The role of secondary prevention becomes increasingly important as it can potentially decrease or eliminate the need for another intervention in these high risk subjects. This project seeks to evaluate the effect of emphasizing secondary prevention measures in this patient population during hospital admission and through six months post-discharge.

Conditions Studied

Interventions

  • OTHER Education

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2009-01
Est. Completion 2013-06
Phase NA

Sponsor

Jeffrey Kramer, MD

1 total trials

What the Registry Record Tells You About NCT00843089

The ClinicalTrials.gov registry entry for NCT00843089 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (91% lower). The listed sponsor is Jeffrey Kramer, MD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Education is the first listed.

NCT00843089 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT00843089 about?

NCT00843089 is a clinical study titled "Secondary Prevention After Coronary Bypass Surgery". Despite immediate symptomatic success after coronary bypass surgery in patients with coronary artery disease, this effect is not sustained over time since risk factors for coronary artery disease are still in place. The role of secondary prevention becomes increasingly important as it can potentiall...

What is the current status of trial NCT00843089?

This trial is currently completed. It is a NA study. The enrollment target is 115 participants. The study started on 2009-01. Estimated completion is 2013-06.

What conditions does trial NCT00843089 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT00843089?

The interventions under investigation include: Education (OTHER).

Who is sponsoring clinical trial NCT00843089?

This trial is sponsored by Jeffrey Kramer, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00843089 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.